ERSTEQ’s Drug
Discovery Insight
Forecasts Made Real
Conventional drug discovery has long centered on identifying ligands with high binding affinity to target proteins. Yet, this ligand-centric paradigm often shows poor correlation with actual biological efficacy and remains inadequate for the vast majority—approximately 80%—of disease-associated proteins deemed “undruggable” due to shallow or inert binding surfaces.
An AI-driven platform now enables deep analysis of the three-dimensional architecture and dynamic conformational behavior of target proteins, predicting biologically relevant interactions not only between proteins and ligands, but also among protein complexes themselves. This target-centric strategy opens the door to the rational discovery of next-generation therapeutics, including protein–protein interaction (PPI) modulators and molecular glue degraders—creating novel treatment pathways for resistant and previously inaccessible targets.
Designed for scalability and cross-modality integration, the platform advances the development of highly selective, precision-engineered small molecules across a broad spectrum of therapeutic areas—paving the way for a new era in drug discovery, shaping tomorrow today.
